



Letter to the editor Re: Standardized assessment of outcome and complications in chronic subdural hematoma: results from a large case series by Bucher B et al.

Laurence Marshman^{1,2}

Received: 15 August 2019 / Accepted: 26 September 2019 / Published online: 21 October 2019
© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Dear Editor

We read with interest the article by Bucher et al. [3] which commendably recorded all complications after chronic subdural hematoma (CSDH) surgery both by type and by the Clavien–Dindo classification. It is agreed that this should now become the standard practice. Importantly, the authors noted a post-operative morbidity of 38.3% [3]. A similarly high rate (47%) was also recently reported by Thomas et al.¹¹. Notably, both rates were significantly higher than the “standard” (10%) proposed by Brennan et al. [2]. Indeed, whilst Brennan et al. [2] had separated out recurrences, even including recurrences (9%) only resulted in a rate of 23% [11]: i.e., still significantly lower than both aforementioned studies [3, 11]. Importantly, the range of complication type observed by Brennan et al. [2] was singularly narrow: e.g., it did not include common complications expected in a CSDH age group, such as delirium [11]. Further, post-operative morbidity in a fractured neck-of-femur cohort (a group frequently compared with CSDH by neurosurgeons [5, 8, 11], including by Brennan et al. [2]) was similar (i.e., 45% [4]) to that of Bucher et al. [3] and Thomas et al.¹¹, but not Brennan et al. [2]. Thus, a “standard” post-operative morbidity of 10% [2] is untenable.

As with others, Bucher et al. [3] state that the length of hospital stay was significantly longer for patients with complications than that for patients without complications (6 vs.

5 days, $P < 0.001$). Unfortunately, however, standard deviations (SD) were not provided [3]. A highly significant P value, with a mean difference of 1 day, implies correspondingly small SD values. Given that length of stay (LOS) may be influenced by numerous administrative factors, in addition to purely clinical factors, a wide range of LOS would have been expected. For example, Brennan et al. [2] found a median LOS of 7 days associated with a range of 1–179 days (although an association with post-operative morbidity was not assessed). Thomas et al. [11] also found a wide range, with a LOS significantly prolonged in those with post-operative morbidity (19.5 ± 8.1 vs. 9.9 ± 14.9 days, $P < 0.01$). Post-operative morbidity which prolongs LOS after major non-neurosurgery is associated with decreased long-term survival [9]. Long-term survival after CSDH is known to be markedly reduced compared with age-matched controls [6]. LOS, like functional impairment at discharge, is therefore an important parameter to exact.

Unfortunately, like most CSDH reports [7], Bucher et al. [3] did not comment on anti-seizure prophylaxis. Since the frequency observed (19%) [3] was significantly higher than that reported by Thomas et al. [11] (5%)—where anti-seizure prophylaxis was uniformly used—this suggests that anti-seizure prophylaxis was not uniformly used by Bucher et al. Interestingly, Battaglia et al. [1] reported no beneficial effect of anti-seizure prophylaxis (4.2%) against controls (5.9%, $P = 0.697$). Unfortunately, the study was retrospective, non-randomized, and too small to determine a null effect [7]: nevertheless, if continued, it could provide useful results [7]. It would therefore be important for Bucher et al. to note the proportion who received anti-seizure prophylaxis in their cohort.

Whilst Buchner et al. [3] found that ASA grade had some utility in predicting the degree of post-operative morbidity, Thomas et al. [11] found that ASA grade, The Physiological and Operative Severity Score for enumeration of Mortality

This article is part of the Topical Collection on *Neurosurgery general*

✉ Laurence Marshman
l.a.g.marshman@btinternet.com

¹ Department of Neurosurgery, The Townsville Hospital, Douglas, Townsville, Queensland 4810, Australia

² School of Medicine and Dentistry, James Cook University, Douglas, Townsville, Queensland 4810, Australia

and Morbidity (POSSUM), and the American College of Surgeons National Surgical Quality Improvement program (ACS-NSQIP) had no utility. Importantly, however, age, pre-existent co-morbidities, and GCS were found to be predictive [11]. Since these latter parameters are incorporated into POSSUM, whilst age and pre-existent co-morbidities incorporated into ACS-NSQIP and pre-existent co-morbidities incorporated into ASA, the predictive failure of POSSUM, ACS-NSQIP, and ASA appeared singular [11]. The authors speculated that factors, such as the incorporation of systemic inflammatory response effects into ASA, POSSUM, and ACS-NSQIP, had proved confounding [11]. However, it would be interesting to see the effect of greater numbers in the cohort of Buchner et al. on POSSUM and ACS-NSQIP.

Finally, the complications recorded suggest that patients with CSDH due to shunt over-drainage were included in the study of Buchner et al. [3], where other studies have excluded these [2, 10, 11]. Future studies should, therefore, include outcome assessments with and without shunted patients to permit comparisons.

A/Prof Laurence AG Marshman

Townsville, Queensland

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

- Battaglia F, Plas B, Melot A, Noudel R, Sol JC, Roche PH, Lubrano V (2015) Is there any benefit from short-term perioperative antiepileptic prophylaxis in patients with chronic subdural haematoma? A retrospective controlled study. *Neurochirurgie* 61(5):324–328. <https://doi.org/10.1016/j.neuchi.2015.06.004>
- Brennan PM, Kolias AG, Joannides AJ, Shapely J, Marcus HJ, Gregson BA, Grover PJ, Hutchinson PJ, Coulter IC (2017) The management and outcome for patients with chronic subdural hematoma: a prospective, multicenter, observational cohort study in the United Kingdom. *British Neurosurgical Trainee Research Collaborative. J Neurosurg* 127(4):732–739. <https://doi.org/10.3171/2016.8.JNS16134>
- Bucher B, Maldaner N, Regli L, Sarnthein J, Serra C (2019) Standardized assessment of outcome and complications in chronic subdural hematoma: results from a large case series. *Acta Neurochir* 161:1297–1304 <https://doi.org/10.1007/s00701-019-03884-7>
- Chia PH, Gualano L, Seevanayagam S, Weinberg L (2013) Outcomes following fractured neck of femur in an Australian metropolitan teaching hospital. *Bone Joint Res* 2(8):162–168. <https://doi.org/10.1302/2046-3758.28.2000177>
- Manickam A, Marshman LAG (2012) Chronic subdural haematoma in the elderly: not a benign disease. *Clin Art Lett J Neurosurg* 117:186–187. <https://doi.org/10.3171/2011.10.JNS111316>
- Manickam A, Marshman LAG, Johnston R (2016) Long-term survival after chronic subdural haematoma. *J Clin Neurosci* 34:100–104
- Marshman L (2019) Is there any benefit from short-term perioperative antiepileptic prophylaxis in patients with chronic subdural haematoma? A retrospective controlled study. *Neurochirurgie*. <https://doi.org/10.1016/j.neuchi.2019.03.003>
- Miranda LB, Braxton E, Hobbs J, Quigley MR (2011) Chronic subdural hematoma in the elderly: not a benign disease. *J Neurosurg* 114:72–76
- Moonesinghe SR, Harris S, Mythen MG, Rowan KM, Haddad FS, Emberton M et al (2014) Survival after postoperative morbidity: a longitudinal observational cohort study. *Br J Anaesth* 113:977–984
- Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jalloh I, Smielewski P et al (2009) Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. *Lancet* 374:1067–1073
- Thomas PAW, Mitchell PS, Marshman LAG (2019) Early postoperative morbidity after chronic subdural hematoma: predictive usefulness of the Physiological and Operative Severity Score for Enumeration of Mortality and Morbidity, American College of Surgeons National Surgical Quality Improvement Program, and American Society of Anesthesiologists Grade in a Prospective Cohort. *World Neurosurg* <https://doi.org/10.1016/j.wneu.2018.12.119>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.